BCM
NRXP icon

Bridgeway Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History

Bridgeway Capital Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,270
Closed -$57.9K – 1320
2024
Q1 		$57.9K Hold
12,270
– – ﹤0.01% 1258
2023
Q4 		$56.4K Sell
12,270
-3,800
-24% -$12.6K ﹤0.01% 1300
2023
Q3 		$41.8K Hold
16,070
– – ﹤0.01% 1316
2023
Q2 		$77.7K Sell
16,070
-7,000
-30% -$42.1K ﹤0.01% 1291
2023
Q1 		$152K Buy
23,070
+5,200
+29% +$52.7K ﹤0.01% 1157
2022
Q4 		$198K Buy
17,870
+2,500
+16% +$25.2K 0.01% 1091
2022
Q3 		$114K Hold
15,370
– – ﹤0.01% 1253
2022
Q2 		$92K Buy
+15,370
New +$202K ﹤0.01% 1237

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bridgeway Capital Management's NRXP Position: Q2 2024 in Review

Bridgeway Capital Management sold out of NRX Pharmaceuticals (NRXP) in Q2 2024, closing a stake of 12,270 shares — an estimated $57.9K sold.

Bridgeway Capital Management first reported a position in NRXP in Q2 2022 and held it in 8 quarters. The position peaked at $198K in Q4 2022. 19 funds tracked by Wall St. Rank hold NRXP as of Q2 2024.

  • Bridgeway Capital Management reported no remaining NRX Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 12,270 NRX Pharmaceuticals shares in Q2 2024, an estimated $57.9K.
  • Bridgeway Capital Management first reported a position in NRX Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Bridgeway Capital Management's NRX Pharmaceuticals position peaked at $198K in Q4 2022.
  • 19 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2024.

Based on Bridgeway Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.